Company research
Bolt Biotherapeutics, Inc.
CIK 1641281Updated Sep 27, 2026
SecurityBOLT · NASDAQ · equity
Name history
Bolt Therapeutics, Inc. · through May 7, 2015
BOLT price & chart
Loading TradingView…
NASDAQ:BOLT on TradingView ↗About the company
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline reflects the Company’s expertise in myeloid biology and cancer drug development. The Company’s lead program is BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1/2 trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company’s Boltbody™ ISAC platform technology. The rest of the Company’s pipeline is currently on hold, including BDC-3042, a Dectin-2 agonist that completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1. For more information, please visit https://www.boltbio.com/.
In the news
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 56,748,000Source | 99,632,000Source | 159,784,000Source | 227,807,000Source |
| Property, Plant and Equipment, NetUSD | 1,245,000Source | 3,139,000Source | 4,957,000Source | 6,453,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,703,000Source | 7,205,000Source | 10,810,000Source | 9,244,000Source |
| Assets, CurrentUSD | 30,260,000Source | 50,814,000Source | 105,708,000Source | 172,746,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,555,000Source | 2,707,000Source | 3,519,000Source | 3,858,000Source |
| Operating Lease, Right-of-Use AssetUSD | 19,230,000Source | 21,756,000Source | 19,120,000Source | 22,072,000Source |
| Other Assets, NoncurrentUSD | 138,000Source | 62,000Source | 1,821,000Source | 1,028,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 30,243,000Source | 42,434,000Source | 47,043,000Source | 56,301,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | 0Source | — |
| Common Stock, Value, IssuedUSD | 0Source | 0Source | 1,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -460,779,000Source | -427,403,000Source | -364,285,000Source | -295,088,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -21,000Source | 97,000Source | 37,000Source | -919,000Source |
| Stockholders' Equity Attributable to ParentUSD | 26,505,000Source | 57,198,000Source | 112,741,000Source | 171,506,000Source |
| Additional Paid in Capital, Common StockUSD | 487,305,000Source | 484,504,000Source | 476,988,000Source | 467,513,000Source |
| Liabilities and EquityUSD | 56,748,000Source | 99,632,000Source | 159,784,000Source | 227,807,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,435,000Source | 15,856,000Source | 20,456,000Source | 23,118,000Source |
| Operating Lease, Liability, CurrentUSD | 2,826,000Source | 2,251,000Source | 2,782,000Source | 2,391,000Source |
| Accounts Payable, CurrentUSD | 1,443,000Source | 1,507,000Source | 2,987,000Source | 3,594,000Source |
| Operating Lease, Liability, NoncurrentUSD | 20,132,000Source | 22,958,000Source | 17,437,000Source | 20,220,000Source |
| Other Liabilities, NoncurrentUSD | 132,000Source | 0Source | 43,000Source | 42,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 31,800,000Source | 70,200,000Source | 128,600,000Source | 192,800,000Source |
| Deferred Revenue, CurrentUSD | 449,000Source | 3,015,000Source | 2,201,000Source | 1,993,000Source |
| Deferred Revenue, NoncurrentUSD | 1,544,000Source | 3,620,000Source | 9,107,000Source | 12,921,000Source |
| Deferred Tax Liabilities, NetUSD | 5,656,000Source | 6,509,000Source | 5,983,000Source | 7,058,000Source |
| Short-term InvestmentsUSD | 15,802,000Source | 40,118,000Source | 91,379,000Source | 159,644,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -33,376,000Source | -63,118,000Source | -69,197,000Source | -88,098,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,291,000Source | 1,781,000Source | 1,854,000Source | 1,666,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,782,000Source | 7,407,000Source | 9,223,000Source | 9,576,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -39,850,000Source | -61,289,000Source | -69,525,000Source | -76,504,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 44,302,000Source | 57,576,000Source | 71,038,000Source | 57,862,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 72,000Source | 41,000Source | 206,000Source | 1,953,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 19,000Source | 108,000Source | 253,000Source | 503,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 4,471,000Source | -3,605,000Source | 1,766,000Source | -18,139,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 13,441,000Source | 8,970,000Source | 12,575,000Source | 10,809,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,782,000Source | 7,407,000Source | 9,223,000Source | 9,576,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 31,800,000Source | 70,200,000Source | 128,600,000Source | 192,800,000Source |
| DepreciationUSD | 1,300,000Source | 1,800,000Source | 1,900,000Source | 1,700,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 288,000Source | 70,000Source | — | — |
| General and Administrative ExpenseUSD | 13,795,000Source | 18,457,000Source | 22,530,000Source | 22,927,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -33,376,000Source | -63,118,000Source | -69,197,000Source | -88,098,000Source |
| Nonoperating Income (Expense)USD | 2,737,000Source | 9,930,000Source | 6,999,000Source | 2,223,000Source |
| Operating ExpensesUSD | 43,808,000Source | 80,738,000Source | 84,072,000Source | 96,050,000Source |
| Proceeds from Issuance of Common StockUSD | 19,000Source | 108,000Source | 253,000Source | 503,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 7,695,000Source | 7,690,000Source | 7,876,000Source | 5,729,000Source |
| Operating Income (Loss)USD | -36,113,000Source | -73,048,000Source | -76,196,000Source | -90,321,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -33,376,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -33,376,000Source | -63,118,000Source | -69,197,000Source | -88,098,000Source |
| Earnings Per Share, BasicUSD per share | -17.85Source | -1.65Source | -1.83Source | -2.36Source |
| Earnings Per Share, DilutedUSD per share | -17.85Source | -1.65Source | -1.83Source | -2.36Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,869,924Source | 38,183,931Source | 37,811,984Source | 37,358,425Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,869,924Source | 38,183,931Source | 37,811,984Source | 37,358,425Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 13,795,000Source | 18,457,000Source | 22,530,000Source | 22,927,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -31,885,000Source | — | — | — |
| Investment Income, NetUSD | 2,496,000Source | 5,255,000Source | 6,999,000Source | 2,223,000Source |
| Labor and Related ExpenseUSD | 13,544,000Source | 23,936,000Source | — | — |
| Nonoperating Income (Expense)USD | 2,737,000Source | 9,930,000Source | 6,999,000Source | 2,223,000Source |
| Operating ExpensesUSD | 43,808,000Source | 80,738,000Source | 84,072,000Source | 96,050,000Source |
| Other ExpensesUSD | — | 2,266,000Source | — | — |
| Other IncomeUSD | 241,000Source | 4,675,000Source | — | — |
| Research and Development ExpenseUSD | 28,533,000Source | 57,469,000Source | 61,542,000Source | 73,123,000Source |
Filing attachments
bolt-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results • Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, CA, August 11, 2026 - Bolt Biotherapeutics (Nasdaq: BOLT), a clinic…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 • Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study REDWOOD CITY, CA, May 1…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2026-03-12
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 • Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, CA, Mar. 12, 2026 - Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-sta…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2025-10-02
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 • Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 • Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, CA, October 1, 2025 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announce…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2025-08-14
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study • Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, CA, August 14, 2025 - Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for t…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2025-05-12
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update • BDC-4182 Phase 1 dose-escalation study now open for enrollment • BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity • Bolt is running a partnering process to advance development of BDC-3042 • Cash balance of $58.0 m…
Read attachment ↗